tiprankstipranks
Advertisement
Advertisement

Bachem AGM Backs Board Proposals and Confirms CHF 0.90 Dividend

Story Highlights
  • Bachem shareholders approved all AGM proposals, including a CHF 0.90 dividend, confirming support for the company’s financial direction.
  • Board members were re-elected, governance bodies refreshed, and reports endorsed, underlining confidence in Bachem’s strategy and oversight.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Claim 55% Off TipRanks

Bachem Holding AG ( (CH:BANB) ) just unveiled an update.

Bachem shareholders endorsed all proposals put forward at the 2026 Annual General Meeting, with 78.3% of voting shares represented, and approved a dividend of CHF 0.90 per share to be paid on May 6, 2026, alongside the adoption of the 2025 annual and consolidated financial statements. The meeting re-elected the Chairman and Board members, refreshed the Compensation Committee with Helma Wennemers as its new chair, approved the sustainability report and auditor appointment of Forvis Mazars SA for 2026, and set out a financial calendar that underscores continued transparency and engagement with investors.

The decisions confirm stable corporate governance and signal ongoing shareholder support for Bachem’s strategic direction as it invests in its peptide and oligonucleotide platform. By backing the compensation structures and sustainability reporting, investors also reinforced confidence in the company’s long-term management framework, which may strengthen its standing in capital markets and its competitiveness in the contract development and manufacturing space.

The most recent analyst rating on (CH:BANB) stock is a Hold with a CHF65.00 price target. To see the full list of analyst forecasts on Bachem Holding AG stock, see the CH:BANB Stock Forecast page.

More about Bachem Holding AG

Bachem Holding AG is a Switzerland-headquartered, innovation-driven manufacturer specializing in the development and production of peptides and oligonucleotides for pharmaceutical and biotechnology clients worldwide. With more than 50 years of experience and operations across Europe, the USA, and Asia, the SIX-listed group supplies products for research, clinical development, and commercial use, positioning it as a key player in the global life sciences supply chain.

Average Trading Volume: 137,363

Technical Sentiment Signal: Strong Buy

Current Market Cap: CHF5.15B

For a thorough assessment of BANB stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1